Blog

ALL TEST COVID19 Rapid Test

Description

A rapid test for the qualitative detection of IgG and IgM antibodies against 2019-nCoV in human whole blood, serum or plasma samples. For professional in vitro diagnostic use only.

Expected Use

The 2019-nCoV IgG/IgM Rapid Test Cassette is a lateral flow chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies against 2019-nCoV in human blood, serum or plasma samples.

Resume

In early January 2020, a new coronavirus (2019-nCoV) was identified as the infectious agent causing an outbreak of viral pneumonia in Wuhan, China, where the first cases had their symptom onset in December 2019. Coronaviruses are enveloped RNA viruses that are widely distributed among humans, other mammals, and birds and cause respiratory, enteric, liver, and neurological diseases. Six species of coronavirus are known to cause disease in humans. Four viruses: 229E, OC43, NL63, and HKU1, are prevalent and generally cause common cold symptoms in immunocompetent people.

The other two strains, severe acute respiratory syndrome coronavirus (SARS-COV) and Middle East respiratory syndrome coronavirus (MERS-COV ), are zoonotic in origin and have been linked to sometimes fatal diseases. Coronaviruses are zoonotic, which means they are transmitted between animals and people. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath, and shortness of breath.

In more severe cases, the infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death. Standard recommendations to prevent the spread of infection include regular hand washing, covering your mouth and nose when coughing and sneezing, cooking meat and eggs thoroughly. Avoid close contact with anyone showing symptoms of respiratory illness, such as coughing and sneezing.

Beginning

The 2019-nCoV IgG/IgM All Test Cassette (Whole Blood/Serum/Plasma) is a qualitative test Membrane-based immunoassay for the detection of IgG and IgM antibodies against 2019-nCoV in whole blood, serum, or plasma samples. This test consists of two components, an IgG component and an IgM component. In the IgG component, anti-human IgG is coated on the IgG test line region. During testing, the sample reacts with 2019-nCoV antigen-coated particles in the test cassette.

The mixture then migrates chromatographically up the membrane by capillary action and reacts with anti-human IgG in the IgG test line region, if the sample contains IgG antibodies to 2019-nCoV. As a result, a coloured line will appear in the IgG test line region. Similarly, anti-human IgM is coated on the IgM test line region and, if the sample contains IgM antibodies to 2019-nCoV, the conjugate-sample complex reacts with anti-human IgM. As a result, a coloured line appears in the IgM test line region.

Therefore, if the sample contains 2019-nCoV IgG antibodies, a coloured line will appear in the IgG test line region. If the sample contains 2019-nCoV IgM antibodies, a coloured line will appear in the IgM test line region. If the sample does not contain 2019-nCoV antibodies, no coloured line will appear in any of the test line regions, indicating a negative result. To serve as a procedural control, a coloured line will always appear in the control line region, indicating that the proper volume of sample has been added and membrane absorption has occurred.

Reagents

The test contains anti-human IgM and anti-human IgG as a capture reagent, 2019-nCoV antigen as a detection reagent. A goat anti-mouse IgG is used in the control line system.

Blog

Saliva Test

Saliva Tests

Saliva testing is a noninvasive collection method in which patients collect their saliva in plastic tubes to measure hormones such as cortisol, estrogens, progesterone, and androgens. This non-invasive saliva collection is ideal for patients because it allows them to collect their samples in the privacy of their homes or office.

Why do we analyze hormones in saliva?

Steroid hormones in the bloodstream are 95-99% bound to carrier proteins and thus are unavailable to target tissues. Saliva tests measure the amount of hormone available to target tissues – the bioavailable amount. For this reason, the saliva test is best related to specific symptoms of excess or deficiency and is a good option for monitoring hormone therapy.

Some analytes cannot be tested using immunoassays, the methodology used for most of our saliva tests. For that reason, ZRT developed an LCMS saliva steroid profile using liquid chromatography/tandem mass spectrometry (LC-MS/MS). This profile analyzes a wide range of bioavailable hormones and hormone metabolites in one convenient collection of saliva samples.

The LCMS test allows accurate reporting of estrogens down to extremely low levels, such as those seen in men, children, and people using aromatase inhibitors, and includes a test for ethinylestradiol, 3-hormone blockers, and melatonin.  ZRT is one of the first laboratories to measure hormones in saliva and helped establish the method that made salivary hormone testing commercially viable for healthcare providers and patients around the world.

The most advanced saliva tests today

  • Supplementation adjusted ranges:

Unlike other labs, patients do not need to stop hormone supplementation to use ZRT tests because we have ranges adjusted for age, menstrual status, and types of supplementation. This is the ideal method for tracking the effectiveness of hormone treatments.

  • No grouping:

ZRT does not pool patient samples, which means we do not pool multiple daily samples to get an average hormone level. Instead, we measured hormones from a single morning sample, which represents the peak of daily hormone production, the optimal time to measure.

  • Extraction:

ZRT is the only laboratory that performs an extraction process for saliva testing, which separates hormones from background contamination. This is the only way to ensure accurate test results for low concentration hormones like estradiol.

  • Establishment of industry standards:

ZRT initiated and manages the industry-wide standards program called the Interlaboratory Saliva Proficiency Testing Program, which enables laboratories to evaluate and improve the accuracy of saliva tests on a regular basis.

Blog

Combo Tests

Expected Use

The Rapid COVID-19 IgM/IgG Combo Test Kit is a lateral flow immunoassay intended for qualitative detection and differentiation of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against SARS-CoV-2 in human serum, acid citrate dextrose (ACD) plasma, and fingerstick whole blood. The fast COVID-19. The IgM/IgG Combination Test Kit is designed to help identify individuals with an adaptive immune system response to SARS-CoV-2, indicating recent or previous infection.

The COVID-19 IgM/IgG Rapid Combination Test Kit should not be used to diagnose or exclude acute SARS-CoV-2 infection. At this time, it is unknown how prolonged antibodies persist after infection and whether the presence of antibodies confers protective immunity. Serum and plasma testing are limited to laboratories certified under the Clinical Laboratory Improvement Program. Amendments of 1988 (CLIA), 42 U.S.C 263a, which meet the requirements for conducting moderate or high operations complexity tests.

Fingerstick testing of whole blood samples is limited to laboratories certified by the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, who meet the requirements to hold a stop, Tests of moderate or waived complexity. The Fingerstick Whole Blood Sample Test is licensed for use in the Point of Care (POC), that is, inpatient care settings operating under a CLIA Certificate of Exemption, Certified of Compliance, or Certificate of Accreditation.

The results are for the detection of IgM and IgG SARS CoV-2 antibodies. IgM and IgG antibodies against SARS-CoV-2 are usually detectable in the blood several days after the initial infection, although the length of time the antibodies are present after infection is not well characterized. People may have a detectable virus present for several weeks after seroconversion.

Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. The sensitivity of the Rapid COVID-19 IgM/IgG Combination Test Kit after early infection is unknown. Negative results do not rule out an acute SARS-CoV-2 infection. If the acute infection is suspected, direct testing for SARS-CoV-2 is necessary.

False-positive results for the Rapid COVID-19 IgM/IgG Combination Test Kit may occur due to cross reactivity of pre-existing antibodies or other possible causes. Due to the risk of false-positive results, confirmation of positive results should be considered using a second, different IgG or IgM assay. The Rapid COVID-19 IgM/IgG Combination Test Kit is for use under the Food and Drug Administration Emergency Use Authorization.

Resume

COVID-19 is an acute infectious disease caused by the SARS-CoV-2 virus. The incubation period of the illness varies from 1 to 14 days, during which time infected people can infect other people. Acute SARSCoV 2 infection can also present without symptoms. Respiratory droplets and contact are the main routes of transmission Initial symptoms of patients include fever, fatigue, and cough, which may develop in dyspnea and other severe manifestations. Some of the severe cases may have acute respiratory distress septic syndrome or shock, or even death.

There is several days of incubation period after infection with the SARS-CoV-2 virus. IgM antibodies can be detected shortly after the incubation period and remain for a short time. IgG antibodies may appear after a few days of incubation period and remain in circulation in the blood for several weeks. A positive IgG result can be an indicator of a recent or previous infection.

Begining

Rapid COVID-19 IgM/IgG Combo Test Kit uses the principle of immunochromatography. Mouse anti-human IgM and human IgG antibodies are immobilized on the nitrocellulose membrane respectively, as two individual test lines (IgM line and IgG line) in the test window of the test device. The IgM line in the test window is closest to the sample well followed by the IgG line. As the test sample flows through the membrane inside the test device, the colloidal gold-recombinant antigen conjugate of the coloured COVID 19 virus is formed complexes with specific antibodies (IgM and/or IgG) against the COVID-19 virus, if present in the sample.

The antigen targets a segment of the SARS-CoV-2 nucleocapsid (N) protein. This complex progresses further the membrane to the test region where it is captured by anti-human IgM and/or human IgG antibodies coated on the membrane leading to the formation of a coloured band, indicating positive test results. The absence of this colour band in the test window indicates a negative test result. A built-in control line always appears in the test window when the test is successful, regardless of the presence or absence of antibodies against the new coronavirus 2019 in the sample.

Supplied Materials

  • COVID-19 IgM/IgG Rapid Combination Test Kit
  • Individual sample buffer
  • 2 μL capillary pipette (serum and plasma only)
  • 5 μL capillary pipette (finger prick only)
  • Sterile safety lancet
  • Insert package

Materials Required But Not Provided

  • Clock or stopwatch, sample collection container, biohazard waste container, disposable gloves, disinfectant.
  • External controls are not included with the kit but are commercially available from Megna Health under catalogue number: RAK-CON-001.

Storage

1. Store the test device at a temperature of 4 to 30o C in the original sealed bag. Do not freeze.
2. The expiration date indicated on the bag was established under these storage conditions.
3. The test device must remain in its original sealed bag until ready for use. After opening, the test device must be used immediately. Do not reuse the device.

Warnings And Precautions

  • For use only under an Emergency Use Authorization. For in vitro diagnostic use only
  • This test has not been licensed or approved by the FDA but has been authorized for emergency use by the FDA under a EUA for use by authorized laboratories.
  • The Fingerstick Whole Blood Sample Test is authorized for use at the point of care (POC), that is, inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or  Certificate of Accreditation.
  • This test has been authorized only to detect the presence of IgM and IgG antibodies against SARS-CoV2, not against other viruses or pathogens.
  • The emergency use of this test is only authorized for the duration of the declaration that the circumstances exist that justify the authorization of the emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1) unless the declaration is terminated or the authorization is revoked earlier.
  • Do not use the product beyond the expiration date.
  • Do not use the product if the bag is damaged or the seal is broken.
  • Handle all specimens as potentially infectious.
  • Follow standard laboratory procedures and biosafety guidelines for handling and disposal of infectious material. When the test procedure is finished, discard the samples based on the relevant status and federal requirements for biological samples.
  • Tests are for single use only.

Preparation For Sample Collection

The serum, ACD plasma, or fingerstick whole blood specimen should be collected according to standard laboratory guidelines terms

1. Heat inactivation of samples, which can cause hemolysis and protein denaturation, should be avoided.
2. The test works best on fresh samples. If the test cannot be performed immediately, serum and plasma ACD can be stored at 2-8ºC for up to 3 days in case of delayed testing. For long-term storage, serum and ACD plasma samples can be frozen at -20ºC for 3 months or at -70ºC for a longer period. avoid repeating
freeze/thaw cycles.

Fingerstick samples must be collected with approved lancets and tested immediately.

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Clia Kits, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells., Vector & Virus

Antigens of Mycobacterium tuberculosis Stimulate CXCR6+ Natural Killer Cells

Natural killer (NK) cells take part in immunity in opposition to a number of pathogens by exerting cytotoxic and cytokine-production actions. Some NK cell subsets additionally mediate recall responses that resemble reminiscence of adaptive lymphocytes in opposition to antigenic and non-antigenic stimuli. The C-X-C motif chemokine receptor 6 (CXCR6) is essential for the event and upkeep of memory-like responses in murine NK cells. In people, a number of subsets of tissue-resident and circulating NK cells with totally different purposeful properties specific CXCR6. However, the function of CXCR6+ NK cells in immunity in opposition to related human pathogens is unknown. Here, we addressed whether or not murine and human CXCR6+ NK cells reply to antigens of Mycobacterium tuberculosis (Mtb). For this function, we evaluated the immunophenotype of hepatic and splenic CXCR6+ NK cells in mice uncovered to a cell-wall (CW) extract of Mtb pressure H37Rv. Also, we characterised the expression of CXCR6 in peripheral NK cells from energetic pulmonary tuberculosis (ATB) sufferers, people with latent TB an infection (LTBI), and wholesome volunteer donors (HD). Furthermore, we evaluated the responses of CXCR6+ NK cells from HD, LTBI, and ATB topics to the in vitro publicity to CW preparations of Mtb H37Rv and Mtb HN878.

Our outcomes confirmed that murine hepatic CXCR6+ NK cells broaden in vivo after consecutive administrations of Mtb H37Rv CW to mice. Remarkably, pooled hepatic and splenic, however not remoted splenic NK cells from handled mice, improve their cytokine manufacturing capability after an in vitro re-challenge with H37Rv CW. In people, CXCR6+ NK cells had been barely detected within the peripheral blood, though barely significative increments within the proportion of CXCR6+, CXCR6+CD49a-, CXCR6+CD49a+, and CXCR6+CD69+ NK cells had been noticed in ATB sufferers as in comparison with HD and LTBI people. In distinction, the growth of CXCR6+CD49a- and CXCR6+CD69+ NK cells in response to the in vitro stimulation with Mtb H37Rv was increased in LTBI people than in ATB sufferers. Finally, we discovered that Mtb HN878 CW generates IFN-γ-producing CXCR6+CD49a+ NK cells. Our outcomes exhibit that antigens of each laboratory-adapted and scientific Mtb strains are stimulating elements for murine and human CXCR6+ NK cells. Future research evaluating the function of CXCR6+ NK cells throughout TB are warranted.

Haploidentical transplantation in sufferers with a number of myeloma making use of pure killer cell alloreactive donors

Disease relapse is a vital downside after allogeneic stem cell transplantations in a number of myeloma (MM). To check the speculation that pure killer (NK) cell alloreactivity within the setting of a haploidentical stem cell transplantation (haploSCT) can cut back the chance of myeloma relapse, we carried out a small potential part 2 examine during which we transplanted poor-risk MM sufferers utilizing a killer cell immunoglobulin-like receptor (KIR)-ligand mismatched haploidentical donor. Patients obtained bone marrow grafts after reduced-intensity conditioning, with post-transplantation cyclophosphamide (PTCY) graft-versus-host-disease (GVHD) prophylaxis. The major endpoint was 1.5-year progression-free survival (PFS); stopping guidelines had been put in in case interim outcomes made a profit of 50% PFS at 1.5 years unlikely.

After inclusion of 12 sufferers, of which 9 had been evaluable for the first endpoint, all sufferers relapsed inside a median time of 90 days. All besides 1 affected person confirmed engraftment, with a median time to neutrophil restoration of 18 (12-30) days. The examine was prematurely terminated primarily based on the predefined stopping guidelines after the inclusion of 12 sufferers. With this small examine, we present that in chemo-resistant myeloma sufferers, NK cell KIR-mismatch just isn’t superior to traditional alloSCT. This technique, nevertheless, can function a platform for brand spanking new remedy ideas.Clinical Trial Registry

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Primary Gastrointestinal Involvement in a Case of Extranodal-Extranasal Natural Killer T Cell Lymphoma

Extra-nasal varieties of Extra-nodal pure killer cell lymphoma (ENKL) have been identified with poorer prognoses than nasal kind with the worst responses to remedy. The present work introduces a case of ENKL with GI involvement with no nasal manifestations. We report a 56-year male farmer with fever, productive cough, dyspnea, anorexia, vomiting and chill along with malaise and cachexia of three months period referred to a hospital with acute stomach ache, and was identified as peritonitis because of perforated terminal ileum ulcer earlier than experiencing surgical procedure as a case of acute stomach. The pathologic examine of the related biopsy confirmed “ulceration and necrosis with dense fibrinoleukocytic exudation and granulation tissue formation. CT scan decided a bilateral mass like haziness which was extra more likely to be metastatic.

The evaluation of the earlier pathologic specimens raised Natural Killer/T cell Lymphoma (NKTL), the explanation for which we centered on the affected person’s sinuses and nasal space in addition to nasopharynx. There was no discovering in examination and endoscopy of sinuses. Pathology additionally discovered malignant excessive grade non-Hodgkin T cell lymphoma in specimens obtained from debridement of ulcer at terminal ileum. It additionally confirmed that almost all of the tumor cells had been optimistic for CD3, CD56, CD8, and LCA however damaging for CD19, CD20 and AE1/AE3.

Positive reactions for CD30 had been proven by some cells. CD56, CD3, and CD8 had been expressed by neoplastic cells and CD30 had been optimistic in few cells. Proliferative exercise (Ki67 index) was excessive (60-70%). This was the primary base to diagnose an extra-nodal extra-nasal NK/T cell lymphoma. In conclusion, Intestinal modifications at center age, particularly in males with nonspecific scientific manifestations is very suggested to be studied pathologically and genetically for T cell varieties like CD30 optimistic T cells that are normally engaged in ENKTL.

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Clia Kits, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells., Vector & Virus

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Recent research have demonstrated that radiotherapy is ready to induce anti-tumor immune responses along with mediating direct cytotoxic results. Cancer-associated fibroblasts (CAFs) are central constituents of the tumor stroma and take part actively in tumor immunoregulation. However, the capability of CAFs to affect immune responses within the context of radiotherapy continues to be poorly understood. This research was undertaken to find out whether or not ionizing radiation alters the CAF-mediated immunoregulatory results on pure killer (NK) cells. CAFs had been remoted from freshly resected non-small cell lung most cancers tissues, whereas NK cells had been ready from peripheral blood of wholesome donors.

Functional assays to review NK cell immune activation included proliferation charges, expression of cell floor markers, secretion of immunomodulators, cytotoxic assays, in addition to manufacturing of intracellular activation markers reminiscent of perforin and granzyme B. Our information present that CAFs inhibit NK cell activation by lowering their proliferation charges, the cytotoxic capability, the extent of degranulation, and the floor expression of stimulatory receptors, whereas concomitantly enhancing floor expression of inhibitory receptors.

Radiation delivered as single high-dose or in fractioned regimens didn’t reverse the immunosuppressive options exerted by CAFs over NK cells in vitro, regardless of triggering enhanced floor expression of a number of checkpoint ligands on irradiated CAFs. In abstract, CAFs mediate noticeable immune inhibitory results on cytokine-activated NK cells throughout co-culture in a donor-independent method. However, ionizing radiation doesn’t intervene with the CAF-mediated immunosuppressive results.

To study the cross-talk between NK cells and DCs in HCV an infection, we remoted monocytes and NK cells from 20 persistent HCV sufferers and 20 wholesome controls. Monocytes had been used to generate immature DCs which had been pulsed with HCV peptides (core, NS3-NS4 and NS5). Four totally different co-cultures had been carried out: E1: each DCs and NK cells had been from a persistent HCV affected person, E2: NK cells from a wholesome management co-cultured with DCs from a persistent HCV affected person, E3:

NK cells from a persistent HCV affected person co-cultured with DCs cells from a wholesome management and E4: each DCs and NK cells had been from a wholesome management. Using stream cytometry, we assessed the impact of those totally different co-cultures on ranges of maturation markers on DCs and ranges of activation/inhibition markers on NK cells. Results confirmed that peptide pulsed HCV DCs confirmed a maturation defect within the type of decreased HLA-DR, decreased CD86 and elevated CD83 expression particularly when co-cultured with HCV NK.

This was primarily as a result of core peptide pulsing and to a lesser extent as a result of NS5 pulsing whereas there was no impact with NS3-NS4 pulsing. Alternatively, HCV NK cells upregulated each activation and inhibition markers particularly when co-cultured with wholesome DCs. Compared to E2, E1 resulted in greater apoptosis of each NK cells and DCs with the proportion of NK apoptosis greater than that of DCs. Taken collectively, the information point out that HCV an infection impairs NK-DC cross-talk which can be a number one trigger in viral persistence and chronicity. This article is protected by copyright. All rights reserved.

Immune checkpoint molecules in pure killer cells as potential targets for most cancers immunotherapy

Recent research have demonstrated the potential of pure killer (NK) cells in immunotherapy to deal with a number of sorts of most cancers. NK cells are innate lymphoid cells that play important roles in tumor surveillance and management that effectively kill the tumor and don’t require the foremost histocompatibility complicated. The discovery of the NK’s potential as a promising therapeutic goal for most cancers is a reduction to oncologists as they face the problem of elevated chemo-resistant cancers. NK cells present nice potential towards stable and hematologic tumors and have progressively proven promise as a therapeutic goal for most cancers immunotherapy. The effector function of those cells is reliant on the steadiness of inhibitory and activating alerts.

Understanding the function of assorted immune checkpoint molecules within the exhaustion and impairment of NK cells when their inhibitory receptors are excessively expressed is especially necessary in most cancers immunotherapy research and scientific implementation. Emerging immune checkpoint receptors and molecules have been discovered to mediate NK cell dysfunction within the tumor microenvironment; this has introduced up the necessity to discover additional further NK cell-related immune checkpoints which may be exploited to reinforce the immune response to refractory cancers. Accordingly, this evaluate will give attention to the current findings in regards to the roles of immune checkpoint molecules and receptors within the regulation of NK cell operate, in addition to their potential software in tumor immunotherapy.

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Natural Killer Cells in Immunotherapy: Are We Nearly There?

atural killer (NK) cells are potent anti-tumor and anti-microbial cells of our innate immune system. They are geared up with an unlimited array of receptors that acknowledge tumor cells and different pathogens. The innate immune exercise of NK cells develops sooner than the adaptive one carried out by T cells, and research counsel an necessary immunoregulatory function for every inhabitants towards the opposite.

The affiliation, noticed in acute myeloid leukemia sufferers receiving haploidentical killer-immunoglobulin-like-receptor-mismatched NK cells, with induction of full remission was the determinant to start an growing variety of scientific research administering NK cells for the therapy of most cancers sufferers. Unfortunately, though transfused NK cells demonstrated security, their noticed efficacy was poor.

Tapered Micro Tips

0-120-0007 3 mm
EUR 344

Tapered Micro Tips 5 mm Diameter Tapered Titanium Micro Tip

0-120-0008 5 mm
EUR 358

10 mm Diameter Solid Titanium Tip

0-120-0009 10 mm
EUR 504

13 mm Diameter Tapped Titanium Tip

0-120-0010 13 mm
EUR 595

13 mm Diameter Solid Titanium Tip

0-120-0011 13 mm
EUR 533

19 mm Diameter Tapped Titanium Tip

0-120-0012 19 mm
EUR 639

19 mm Diameter Solid Titanium Tip

0-120-0013 19 mm
EUR 570

25 mm Diameter Tapped Titanium Tip

0-120-0014 25 mm
EUR 682

25 mm Diameter Solid Titanium Tip

0-120-0015 25 mm
EUR 614

Flat Replaceable Tips 13 mm Diameter Flat Titanium Tip

0-120-0016 13 mm
EUR 86
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 19 mm Diameter Flat Titanium Tip

0-120-0017 19 mm
EUR 92
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip

0-120-0018 25 mm
EUR 100
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Titanium Cup Tip, 250 ml

0-120-0019 250 ml
EUR 1377
Description: includes Interface Washers

Microtube Tray, 8 Position (for 250 ml Cup Tip)

0-120-0021 each
EUR 113
Description: includes Interface Washers

Continuous Flow Chamber

0-120-0026 each
EUR 774
Description: includes Interface Washers

Interface Washers 1.5” Diameter, 5/Pkg

0-120-003 1.5'' Diameter
EUR 31

13 mm Diameter Solid Titanium Extender Tip

0-120-0032 13 mm
EUR 301

13 mm Diameter Tapped Titanium Extender Tip

0-120-0033 13 mm
EUR 362

19 mm Diameter Solid Titanium Extender Tip

0-120-0034 19 mm
EUR 315

19 mm Diameter Tapped Titanium Extender Tip

0-120-0035 19 mm
EUR 375

25 mm Diameter Solid Titanium Extender Tip

0-120-0036 25 mm
EUR 328

25 mm Diameter Tapped Titanium Extender Tip

0-120-0037 25 mm
EUR 389

KoldPod, 1.5ml Micro Tube

0-120-0038 1.5 ml
EUR 152
Description: Thermo conductive tube pods

KoldPod, 15ml Conical Tube

0-120-0039 15 ml
EUR 275
Description: Thermo conductive tube pods

KoldPod, 50ml Conical Tube

0-120-0040 50 ml
EUR 290
Description: Thermo conductive tube pods

Model 150 V/T Ultrasonic Homogenizer

0-121-0002 210-240V/50-60Hz
EUR 2920
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing.

Model 300 V/T Ultrasonic Homogenizer

0-122-0002 210-240V/50-60Hz
EUR 3520
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample.

SONABOZ Sound Abating Chamber

0-125-0001 each
EUR 1020
Description: Reduces cavitational sound emitted during processing.

Model 3000 Ultrasonic Homogenizer

0-127-0002 210-240V/50-60Hz
EUR 4120
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample.

Model 3000MP Ultrasonic Homogenizer

0-128-0002 210-240V/50-60Hz
EUR 4720
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing.

OMNICON® Zone Reader, 210-240V/50-60Hz

0-131-0002 210-240V/50-60Hz
EUR 35200
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media.

OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz

0-134-0002 210-240V/50-60Hz
EUR 32200
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample.

Peni Cylinder Dispenser with Manual Hopper

0-144-0002 each
EUR 5406
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish.

Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz

0-144-0003 100-240V/50-60Hz
EUR 6254
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection.

Stainless Steel Peni Cylinder with Flat Face

0-144-0005 6mm I.D. x 8mm O.D. x 10mm Long
EUR 399
Description: sold in packages of 100 pieces

Stainless Steel Peni Cylinder with Chamfered Face

0-144-0006 6mm I.D. x 8mm O.D. x 10mm Long
EUR 412
Description: sold in packages of 100 pieces

Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA)

000-CUS Custom
EUR 602

Alpha-Bungarotoxin, CF®405S, 500 ug

00002 1UG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-bungarotoxin, CF405s

00002 500uG
EUR 594
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF®405S, 500 ug

00002-1 EA
EUR 527

Alpha-Bungarotoxin, CF®405S 100ug

00002-100ug 100uG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

00003-1 EA
EUR 527

Alpha-Bungarotoxin, CF®680R 100ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

00004-1 EA
EUR 527

Alpha-Bungarotoxin, CF®640R 100ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

00005-1 EA
EUR 527

Alpha-Bungarotoxin CF®488A 100ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

00006-1 EA
EUR 527

Alpha-Bungarotoxin, CF®568 100ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

00007-1 EA
EUR 527

Alpha-Bungarotoxin CF®594 100ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

00009-1 EA
EUR 527

Alpha-Bungarotoxin, CF®633 100ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, 1 mg

00010-1 1MG
EUR 193
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, 1 mg

00010-1-1 EA
EUR 193

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011 500uG
EUR 376
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011-1 EA
EUR 376

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012 500uG
EUR 394
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012-1 EA
EUR 394

Fluorescein-alpha-bungarotoxin, 10x50ug

00013 10ST
EUR 436
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-alpha-bungarotoxin, 10x50ug

00013-1 EA
EUR 436

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014 10ST
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015 500uG
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016 10ST
EUR 560
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016-1 EA
EUR 560

Biotin-XX-A-Bungarotoxin, 500 ug

00017 500uG
EUR 455
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Biotin-XX-A-Bungarotoxin, 500 ug

00017-1 EA
EUR 455

Alpha-Bungarotoxin, CF®555, 500 ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®555, 500 ug

00018-1 EA
EUR 527

Alpha-Bungarotoxin, CF®555 100ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Acrylamide, Chemzymes Ultra Pure®

00019-100 100g
EUR 91
Description: 79-06-1

Acrylamide, Chemzymes Ultra Pure®

00019-500 500g
EUR 241
Description: 79-06-1

Biotin-cAMP, 1 mg

00020 1MG
EUR 298
Description: N/A

Biotin-cAMP, 1 mg

00020-1 20ST
EUR 298
Description: N/A

Biotin-cAMP, 50 ug

00020-1-1 EA
EUR 414

Biotin-cGMP, 1 mg

00021 1MG
EUR 331
Description: N/A

Biotin-cGMP, 1 mg

00021-1 20ST
EUR 331
Description: N/A

Biotin-cGMP, 20x50 ug

00021-1-1 EA
EUR 447

Cyanine 644-cAMP, 1 mg

00022 1MG
EUR 496
Description: N/A

Cyanine 644-cAMP, 1 mg

00022-1 20ST
EUR 496
Description: N/A

Cyanine 644-cAMP, 20x50 ug

00022-1-1 EA
EUR 647

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023 1MG
EUR 285
Description: N/A

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023-1 EA
EUR 285

Staurosporine

00025 100uG
EUR 100
Description: N/A

Staurosporine

00025-1 EA
EUR 100

Alpha-Bungarotoxin, CF®543, 500 ug

00026 500uG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®543, 500 ug

00026-1 EA
EUR 527

Alpha-Bungarotoxin, CF®543, 100 ug

00026-100ug 1UG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Rhodamine Phalloidin 300U

00027 300
EUR 364
Description: N/A

Rhodamine Phalloidin 300U

00027-1 EA
EUR 364

Biotin-XX-Phalloidin

00028 100U
EUR 466
Description: N/A

Biotin-XX-Phalloidin

00028-1 EA
EUR 466

Fluorescein-Phalloidin

00030 300U
EUR 364
Description: N/A

Fluorescein-Phalloidin

00030-1 EA
EUR 364

Rhodamine 110 Phalloidin

00032 300ST
EUR 364
Description: N/A

Rhodamine 110 Phalloidin

00032-1 EA
EUR 364

Sulforhodamine 101 (Texas Red®) Phalloidin

00033 300EU
EUR 364
Description: N/A

Sulforhodamine 101 (Texas Red®) Phalloidin

00033-1 EA
EUR 364

Phalloidin, CF®405M

00034 300U
EUR 482
Description: N/A

Phalloidin, CF®405M

00034-1 EA
EUR 482

Phalloidin, CF®405M

00034-T 50U
EUR 101
Description: N/A

Phalloidin, CF®405M

00034-T-1 EA
EUR 101

CF®488A-cAMP

00036 100ug
EUR 136
Description: N/A

CF®488A-cAMP

00036-1 EA
EUR 136

CF®640R-cAMP

00037 100ug
EUR 136
Description: N/A

CF®640R-cAMP

00037-1 EA
EUR 136

Phalloidin, CF555

00040 300U
EUR 530.4
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF555

00040-T 50U
EUR 159.6
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF®647, 300 U

00041 300U
EUR 482
Description: N/A

Phalloidin, CF®647, 300 U

00041-1 EA
EUR 482

Phalloidin, CF®647, 50 U

00041-T 50U
EUR 101
Description: N/A

Phalloidin, CF®647, 50 U

00041-T-1 EA
EUR 101

Phalloidin, CF®488A, 300 U

00042 300U
EUR 482
Description: N/A

Phalloidin, CF®488A, 300 U

00042-1 EA
EUR 482

Phalloidin, CF®488A, 50 U

00042-T 50U
EUR 101
Description: N/A

In current years, novel research have emerged, combining NK cells with different immunotherapeutic brokers, reminiscent of monoclonal antibodies, which could enhance scientific efficacy. Moreover, genetically-modified NK cells aimed toward arming NK cells with higher efficacy and persistence have appeared as another choice. Here, we evaluate novel pre-clinical and scientific research printed within the final 5 years administering NK cells as a monotherapy and mixed with different brokers, and we additionally evaluate chimeric antigen receptor-modified NK cells for the therapy of most cancers sufferers.

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells.

The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function

Natural killer (NK) cells are innate lymphoid cells, which play key roles in elimination of virally contaminated and malignant cells. The steadiness between activating and inhibitory alerts derived from NK floor receptors govern the NK cell immune response. The cytoskeleton facilitates most NK cell effector capabilities, akin to motility, infiltration, conjugation with goal cells, immunological synapse meeting, and cytotoxicity. Though many research have characterised signaling pathways that promote actin reorganization in immune cells, it isn’t utterly clear how specific cytoskeletal architectures at the immunological synapse promote effector capabilities, and how cytoskeletal dynamics influence downstream signaling pathways and activation.

Moreover, pioneering research using superior imaging methods have solely begun to uncover the architectural complexity dictating the NK cell activation threshold; it’s changing into clear {that a} distinct group of the cytoskeleton and signaling receptors at the NK immunological synapse performs a decisive position in activation and tolerance. Here, we evaluate the roles of the actin cytoskeleton in NK cells. We deal with how actin dynamics influence cytolytic granule secretion, NK cell motility, and NK cell infiltration by way of tissues into inflammatory websites. We can even describe the further cytoskeletal elements, non-muscle Myosin II and microtubules that play pivotal roles in NK cell exercise.

Expression of programmed cell loss of life protein 1 (PD-1) on pure killer (NK) cells has been tough to analyze on human NK cells. By testing industrial clones and novel anti-PD-1 reagents, we discovered expression of practical PD-1 on resting human NK cells in wholesome people and reconstituting NK cells early after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Peripheral blood samples from wholesome people and transplant recipients had been stained for PD-1 expression utilizing the industrial anti-PD-1 clone PD1.3.1.3, fluorescein isothiocyanate (FITC)-labeled pembrolizumab, or an FITC-labeled single-chain variable fragment (scFv) reagent comprised of pembrolizumab.
These reagents recognized low but constant basal PD-1 expression on resting NK cells, a discovering verified by discovering decrease PD-1 transcripts in sorted NK cells in contrast with these in resting or activated T cells. An enhance in PD-1 expression was recognized on paired resting NK cells after allo-HSCT. Blockade of PD-1 on resting NK cells from wholesome donors with pembrolizumab didn’t improve NK operate towards programmed death-ligand 1 (PD-L1)-expressing tumor traces, however blocking with its scFv by-product resulted in a twofold enhance in NK cell degranulation and up to a fourfold enhance in cytokine manufacturing.
In assist of this mechanism, PD-L1 overexpression of Okay562 targets suppressed NK cell operate. Interleukin-15 (IL-15) exercise was potent and couldn’t be additional enhanced by PD-1 blockade. An identical enhance in operate was noticed with scFv PD-1 blockade on resting blood NK cells after allo-HSCT. We determine the practical significance of the PD-1/PD-L1 axis on human NK cells in which blockade or activation to overcome inhibition will improve NK cell-mediated antitumor management. Furthermore, particular emphasis might be positioned on the position of the cytoskeleton in meeting of immunological synapses, and how mutations or downregulation of cytoskeletal accent proteins influence NK cell operate in well being and illness.
The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function

Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?

 

Large granular lymphocyte leukemias (LGLL) are sustained by proliferating cytotoxic T cells or NK cells, as occurs in Chronic Lymphoproliferative Disorder of Natural Killer cells (CLPD-NK), whose etiology is simply partly understood. Different hypotheses have been proposed on the unique occasions triggering NK cell hyperactivation and transformation, together with a job of viral brokers. In this angle, we revise the traces of proof that steered a pathogenetic position in LGLL of the publicity to retroviruses and that recognized Epstein Barr Virus (EBV) in different NK cell leukemias and lymphomas and deal with the contrasting information about the significance of viral brokers in CLPD-NK.

EBV was detected in aggressive NK leukemias however not in the indolent CLPD-NK, the place seroreactivity towards HTLV-1 retrovirus envelope BA21 protein antigens has been reported in sufferers, though missing clear proof of HTLV an infection. We subsequent current unique outcomes of complete exome sequencing information evaluation that failed to determine viral sequences in CLPD-NK. We not too long ago demonstrated that proliferating NK cells of sufferers harbor a number of somatic lesions probably contributing to maintain NK cell proliferation.

Thus, we discover whether or not “neoantigens” comparable to the BA21 antigen might be generated by aberrancies current in the leukemic clone. In gentle of the literature and new information, we evaluated the intriguing speculation that NK cell activation will be attributable to retroviral brokers situated outdoors the hematopoietic compartment and on the potential mechanisms concerned with the prospects of immunotherapy-based approaches to restrict the progress of NK cells in CLPD-NK illness.

Tapered Micro Tips

0-120-0007 3 mm
EUR 344

Tapered Micro Tips 5 mm Diameter Tapered Titanium Micro Tip

0-120-0008 5 mm
EUR 358

10 mm Diameter Solid Titanium Tip

0-120-0009 10 mm
EUR 504

13 mm Diameter Tapped Titanium Tip

0-120-0010 13 mm
EUR 595

13 mm Diameter Solid Titanium Tip

0-120-0011 13 mm
EUR 533

19 mm Diameter Tapped Titanium Tip

0-120-0012 19 mm
EUR 639

19 mm Diameter Solid Titanium Tip

0-120-0013 19 mm
EUR 570

25 mm Diameter Tapped Titanium Tip

0-120-0014 25 mm
EUR 682

25 mm Diameter Solid Titanium Tip

0-120-0015 25 mm
EUR 614

Flat Replaceable Tips 13 mm Diameter Flat Titanium Tip

0-120-0016 13 mm
EUR 86
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 19 mm Diameter Flat Titanium Tip

0-120-0017 19 mm
EUR 92
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip

0-120-0018 25 mm
EUR 100
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Titanium Cup Tip, 250 ml

0-120-0019 250 ml
EUR 1377
Description: includes Interface Washers

Microtube Tray, 8 Position (for 250 ml Cup Tip)

0-120-0021 each
EUR 113
Description: includes Interface Washers

Continuous Flow Chamber

0-120-0026 each
EUR 774
Description: includes Interface Washers

Interface Washers 1.5” Diameter, 5/Pkg

0-120-003 1.5'' Diameter
EUR 31

13 mm Diameter Solid Titanium Extender Tip

0-120-0032 13 mm
EUR 301

13 mm Diameter Tapped Titanium Extender Tip

0-120-0033 13 mm
EUR 362

19 mm Diameter Solid Titanium Extender Tip

0-120-0034 19 mm
EUR 315

19 mm Diameter Tapped Titanium Extender Tip

0-120-0035 19 mm
EUR 375

25 mm Diameter Solid Titanium Extender Tip

0-120-0036 25 mm
EUR 328

25 mm Diameter Tapped Titanium Extender Tip

0-120-0037 25 mm
EUR 389

KoldPod, 1.5ml Micro Tube

0-120-0038 1.5 ml
EUR 152
Description: Thermo conductive tube pods

KoldPod, 15ml Conical Tube

0-120-0039 15 ml
EUR 275
Description: Thermo conductive tube pods

KoldPod, 50ml Conical Tube

0-120-0040 50 ml
EUR 290
Description: Thermo conductive tube pods

Model 150 V/T Ultrasonic Homogenizer

0-121-0002 210-240V/50-60Hz
EUR 2920
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing.

Model 300 V/T Ultrasonic Homogenizer

0-122-0002 210-240V/50-60Hz
EUR 3520
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample.

SONABOZ Sound Abating Chamber

0-125-0001 each
EUR 1020
Description: Reduces cavitational sound emitted during processing.

Model 3000 Ultrasonic Homogenizer

0-127-0002 210-240V/50-60Hz
EUR 4120
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample.

Model 3000MP Ultrasonic Homogenizer

0-128-0002 210-240V/50-60Hz
EUR 4720
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing.

OMNICON® Zone Reader, 210-240V/50-60Hz

0-131-0002 210-240V/50-60Hz
EUR 35200
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media.

OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz

0-134-0002 210-240V/50-60Hz
EUR 32200
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample.

Peni Cylinder Dispenser with Manual Hopper

0-144-0002 each
EUR 5406
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish.

Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz

0-144-0003 100-240V/50-60Hz
EUR 6254
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection.

Stainless Steel Peni Cylinder with Flat Face

0-144-0005 6mm I.D. x 8mm O.D. x 10mm Long
EUR 399
Description: sold in packages of 100 pieces

Stainless Steel Peni Cylinder with Chamfered Face

0-144-0006 6mm I.D. x 8mm O.D. x 10mm Long
EUR 412
Description: sold in packages of 100 pieces

Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA)

000-CUS Custom
EUR 602

Alpha-Bungarotoxin, CF®405S, 500 ug

00002 1UG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-bungarotoxin, CF405s

00002 500uG
EUR 594
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF®405S, 500 ug

00002-1 EA
EUR 527

Alpha-Bungarotoxin, CF®405S 100ug

00002-100ug 100uG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

00003-1 EA
EUR 527

Alpha-Bungarotoxin, CF®680R 100ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

00004-1 EA
EUR 527

Alpha-Bungarotoxin, CF®640R 100ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

00005-1 EA
EUR 527

Alpha-Bungarotoxin CF®488A 100ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

00006-1 EA
EUR 527

Alpha-Bungarotoxin, CF®568 100ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

00007-1 EA
EUR 527

Alpha-Bungarotoxin CF®594 100ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

00009-1 EA
EUR 527

Alpha-Bungarotoxin, CF®633 100ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, 1 mg

00010-1 1MG
EUR 193
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, 1 mg

00010-1-1 EA
EUR 193

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011 500uG
EUR 376
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011-1 EA
EUR 376

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012 500uG
EUR 394
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012-1 EA
EUR 394

Fluorescein-alpha-bungarotoxin, 10x50ug

00013 10ST
EUR 436
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-alpha-bungarotoxin, 10x50ug

00013-1 EA
EUR 436

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014 10ST
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015 500uG
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016 10ST
EUR 560
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016-1 EA
EUR 560

Biotin-XX-A-Bungarotoxin, 500 ug

00017 500uG
EUR 455
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Biotin-XX-A-Bungarotoxin, 500 ug

00017-1 EA
EUR 455

Alpha-Bungarotoxin, CF®555, 500 ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®555, 500 ug

00018-1 EA
EUR 527

Alpha-Bungarotoxin, CF®555 100ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Acrylamide, Chemzymes Ultra Pure®

00019-100 100g
EUR 91
Description: 79-06-1

Acrylamide, Chemzymes Ultra Pure®

00019-500 500g
EUR 241
Description: 79-06-1

Biotin-cAMP, 1 mg

00020 1MG
EUR 298
Description: N/A

Biotin-cAMP, 1 mg

00020-1 20ST
EUR 298
Description: N/A

Biotin-cAMP, 50 ug

00020-1-1 EA
EUR 414

Biotin-cGMP, 1 mg

00021 1MG
EUR 331
Description: N/A

Biotin-cGMP, 1 mg

00021-1 20ST
EUR 331
Description: N/A

Biotin-cGMP, 20x50 ug

00021-1-1 EA
EUR 447

Cyanine 644-cAMP, 1 mg

00022 1MG
EUR 496
Description: N/A

Cyanine 644-cAMP, 1 mg

00022-1 20ST
EUR 496
Description: N/A

Cyanine 644-cAMP, 20x50 ug

00022-1-1 EA
EUR 647

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023 1MG
EUR 285
Description: N/A

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023-1 EA
EUR 285

Staurosporine

00025 100uG
EUR 100
Description: N/A

Staurosporine

00025-1 EA
EUR 100

Alpha-Bungarotoxin, CF®543, 500 ug

00026 500uG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®543, 500 ug

00026-1 EA
EUR 527

Alpha-Bungarotoxin, CF®543, 100 ug

00026-100ug 1UG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Rhodamine Phalloidin 300U

00027 300
EUR 364
Description: N/A

Rhodamine Phalloidin 300U

00027-1 EA
EUR 364

Biotin-XX-Phalloidin

00028 100U
EUR 466
Description: N/A

Biotin-XX-Phalloidin

00028-1 EA
EUR 466

Fluorescein-Phalloidin

00030 300U
EUR 364
Description: N/A

Fluorescein-Phalloidin

00030-1 EA
EUR 364

Rhodamine 110 Phalloidin

00032 300ST
EUR 364
Description: N/A

Rhodamine 110 Phalloidin

00032-1 EA
EUR 364

Sulforhodamine 101 (Texas Red®) Phalloidin

00033 300EU
EUR 364
Description: N/A

Sulforhodamine 101 (Texas Red®) Phalloidin

00033-1 EA
EUR 364

Phalloidin, CF®405M

00034 300U
EUR 482
Description: N/A

Phalloidin, CF®405M

00034-1 EA
EUR 482

Phalloidin, CF®405M

00034-T 50U
EUR 101
Description: N/A

Phalloidin, CF®405M

00034-T-1 EA
EUR 101

CF®488A-cAMP

00036 100ug
EUR 136
Description: N/A

CF®488A-cAMP

00036-1 EA
EUR 136

CF®640R-cAMP

00037 100ug
EUR 136
Description: N/A

CF®640R-cAMP

00037-1 EA
EUR 136

Phalloidin, CF555

00040 300U
EUR 530.4
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF555

00040-T 50U
EUR 159.6
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF®647, 300 U

00041 300U
EUR 482
Description: N/A

Phalloidin, CF®647, 300 U

00041-1 EA
EUR 482

Phalloidin, CF®647, 50 U

00041-T 50U
EUR 101
Description: N/A

Phalloidin, CF®647, 50 U

00041-T-1 EA
EUR 101

Phalloidin, CF®488A, 300 U

00042 300U
EUR 482
Description: N/A

Phalloidin, CF®488A, 300 U

00042-1 EA
EUR 482

Phalloidin, CF®488A, 50 U

00042-T 50U
EUR 101
Description: N/A

Phalloidin, CF®488A, 50 U

00042-T-1 EA
EUR 101

Phalloidin, CF®543, 300 U

00043 300U
EUR 482
Description: N/A

Phalloidin, CF®543, 300 U

00043-1 EA
EUR 482

Phalloidin, CF®543, 50 U

00043-T 50U
EUR 101
Description: N/A

Phalloidin, CF®543, 50 U

00043-T-1 EA
EUR 101

Phalloidin, CF®568, 300 U

00044 300U
EUR 482
Description: N/A

Phalloidin, CF®568, 300 U

00044-1 EA
EUR 482

Phalloidin, CF®568, 50 U

00044-T 50U
EUR 101
Description: N/A

Phalloidin, CF®568, 50 U

00044-T-1 EA
EUR 101

This part 2 research with Simon’s two-stage design evaluated daratumumab in sufferers with histologically confirmed extranodal NKTCL, nasal kind, per WHO classification that was refractory to or relapsed after ≥ 1 line of chemotherapy, who weren’t candidates for different remedy modalities. All sufferers obtained daratumumab 16 mg/kg intravenously as soon as weekly for Cycles 1 and 2, each different week for Cycles Three by way of 6, and each four weeks thereafter till development or unacceptable toxicity; all cycles had been 28 days. The main finish level was goal response price (ORR) based mostly on blinded impartial central evaluate per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin Lymphoma (Lugano classification).